Authors : Dony. D.; Jackson Selvin. Y.; Joseph Chinnappa Raj. J.

Volume/Issue : Volume 10 - 2025, Issue 5 - May

Google Scholar : https://tinyurl.com/3fmybb6r

DOI : https://doi.org/10.38124/ijisrt/25may245

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Respiratory disease, including asthma and Chronic Obstructive Pulmonary Disease (COPD), presents significant challenges in patient management and quality of life. Nebulizers are commonly used to deliver inhaled medications directly to the lungs, offering advantages for patients who struggle with traditional inhalers. However, the safety and efficacy of nebulizer treatments require thorough evaluation. This prospective cohort study aims to assess patient-reported outcomes, adherence to treatment regimens, and any adverse effects associated with nebulizer use. By analyzing these factors, the research seeks to inform clinical practices, enhance patient education, and develop guidelines to optimize the use of nebulizers in lung disease management. The study is on prospective observational cohort study was carried at a tertiary care hospital in erode, focusing on the nebulizer use patients for lung disease over a period of 9 months; the estimated sample size is 157 in were 22 patients were not involved in follow-up data were collected based on the questionnaires. The questioner is in 3section disease based, efficacy of drug and safety maintenance. In my study out of 157 patients, a male patient is highly affected by the respiratory disease. In hospital, 68% of the patient used the continuous nebulization. Albuterol drug is effective for asthma patients and combination of ipratropium bromide and levosalbutamol is effective in cod patients. Continuous nebulizer therapy in optimizing outcomes for respiratory patients and highlight the need for ongoing support to ensure patient comfort and satisfaction. My finding the use of albuterol for asthma and the combination of ipratropium bromide and levosalbutamol for COPD highlight the importance of proper medication use in enhancing clinical outcomes.

Keywords : Respiratory Disorder, Nebulizer, Asthma, COPD.

References :

1. Gayle, Cosetta Minelli Respiratory-related death in individuals with incident asthma and COPD: a competing risk analysis Alicia. BMC Pulm Med. 2022 Jan 8; 22:28.
2. Tetyana Kendzerska , Teresa M To  The impact of a history of asthma on long-term outcomes of people with newly diagnosed chronic obstructive pulmonary disease: A population study doi: 10.1016/j.jaci.2016.06.026. Epub 2016 Sep 15 
3. Deyu Zhao, Dehui Chen, and CARE: an observational study of adherence to home nebulizer therapy among children with asthma, Ther Adv Respir Dis. 2021 Feb 4; 15:1753466620986391. doi: 10.1177/1753466620986391
4. Global Initiative for Asthma. Global strategy for asthma management and prevention (2016, accessed 23 October 2020)
5. Diagnostic Spirometry in Primary Care Proposed standards for general practice compliant with American Thoracic Society and European Respiratory Society recommendations. Prim Care Respir J. 2009 Aug 14;18 (3):130–147.
6. Dave Singh, Alvar Agusti, Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019, European Respiratory Journal 2019 53(5): 1900164;
7. Timm Greulich 1, Alan Altraja, Protocol for the EARCO Registry: a pan-European observational study in patients with α1-antitrypsin deficiency. ERJ Open Res. 2020 Mar 2;6(1):00181-2019.
8. Mohammed A Almeshari, Nowaf Y Alobaidi, Small Airways Response to Bronchodilators in Adults with Asthma or COPD: A Systematic Review. Int J Chron Obstruct Pulmon Dis. 2021 Nov 11; 16:3065–3082.
9. Omar S Usmani , Dave Singh, The prevalence of small airways disease in adult asthma: A systematic literature review. Respir Med 2016 Jul: 116:19-27. doi: 10.1016/j.rmed.2016.05.006.
10. Tan WC, Vollmer WM, Lamprecht B, et al. Worldwide patterns of bronchodilator responsiveness: results from the Burden of Obstructive Lung Disease study. Thorax. 2012; 67 (8):718–726. doi: 10.1136/thoraxjnl-2011-201445. 
11. Wouter H van Geffen, Orestes A Carpaij, Long-acting dual bronchodilator therapy (indacaterol/glycopyrronium) versus nebulized short-acting dual bronchodilator (salbutamol/ipratropium) in chronic obstructive pulmonary disease: A double-blind, randomized, placebo-controlled trial. Respir Med. 2020 Sep: 171:106064.  doi:10.1016/j.rmed.2020.106064.  Epub 2020 Jul 3.
12. Goodman, N. Morgan, M. Nikander,Evaluation of patient-reported outcomes and quality of life with the I-neb AAD system in patients with chronic obstructive pulmonary disease J. Aerosol Med. Pulm. Drug Deliv. 2010; Apr 23. (Suppl 1):S-61–S-70.
13. van Geffen, W.H.  Slebos, D.J.  Kerstjens, H.A.M.Hyperinflation in COPD exacerbations DOI: 10.1016/S2213-2600(15)00459-2 Lancet Respir. Med. 2015; Dec; 3 (12):e43-4.
14. O'Donnell DE, Parker CM, COPD exacerbations. 3: Pathophysiology.  Thorax.2006 Apr;61(4):354–361. 
15. Prapasri Kulalert, Phichayut Phinyo, and Continuous versus intermittent short-acting β2-agonists nebulization as first-line therapy in hospitalized children with severe asthma exacerbation: a propensity score matching analysis. Asthma Res Pract. 2020 Jul 2:6:6.
16. Gustavo J Rodrigo, Carlos Rodrigo, Continuous vs intermittent beta-agonists in the treatment of acute adult asthma: a systematic review with meta-analysis. Chest 2002 Jul; 122 (1):160-5. doi: 10.1378/chest.122.1.160.
17. F. W. Moler, M. E. Hurwitz, Improvement in clinical asthma score and Paco2 in children with severe asthma treated with continuously nebulized terbutaline. J Allergy Clin Immunol. 1988 Jun;81(6):1101-9. 
18. Ceyhan Y., The Experiences of Individuals With a History of Acute Exacerbations of COPD and Their Thoughts on Death: Empirical Qualitative Research, Chronic obstructive pulmonary diseases. Chronic Obstr Pulm Dis. 2023 Jul 26; 10 (3):259-269.
19. Ceyhan Y. and Tekinsoy Kartin P., The Effects of Breathing Exercises and Inhaler Training in Patients With COPD on the Severity of Dyspnea and Life Quality: A Randomized Controlled Trial, Trials. 2022 Aug 26; 23 (1):707.
20. O’Donnell D. E., Milne K. M., James M. D, et al., Dyspnea in COPD: New Mechanistic Insights and Management Implications, Advances in Therapy. Adv Ther. 2020 Jan; 37 (1):41-60.
21. Biney I. N., Ari A., Barjaktarevic I. Z. et al., Guidance on Mitigating the Risk of Transmitting Respiratory Infections during Nebulization by the COPD Foundation Nebulizer Consortium,  Chest. 2024 Mar; 165 (3):653-668.
22. Paul D. Terry. Rajiv Dhand., The 2023 GOLD Report: Updated Guidelines for Inhaled Pharmacological Therapy in Patients with Stable COPD. Pulm Ther. 2023 Jul 20;9 (3):345–357.